OTLK Share Price Performance
US$1.09
-4.02 (-78.67%)
Price US$1.09
Share PriceUS$1.09
Outlook Therapeutics, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 16 Fair Values set on narratives written by author
OTLK Community Narratives
There are no narratives available yet.
Recent OTLK News & Updates
Outlook Therapeutics, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.98
- Gross Margin
- -2,681.93%
- Net Profit Margin
- -2,885.82%
- Debt/Equity Ratio
- -92.6%
Outlook Therapeutics, Inc. Competitors
Snowflake Analysis
About OTLK
- Founded
- 2010
- Employees
- 23
- CEO
- WebsiteView website
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
U.S. Market Performance
- 7 Days: 1.1%
- 3 Months: 8.9%
- 1 Year: 18.9%
- Year to Date: 15.1%
Over the last 7 days, the market has risen 1.1%, driven by gains of 1.9% in the Information Technology sector. As for the past 12 months, the market is up 19%. Looking forward, earnings are forecast to grow by 15% annually. Market details ›